Homozygous Familial Hypercholesterolemia (HoFH)

European Commission extends Evkeeza approval to children as young as 6 months with HoFH

The European Commission has extended the approval of Evkeeza (evinacumab) to include children as young as 6 months old with homozygous familial hypercholesterolemia (HoFH), an ultrarare inherited condition characterized by dangerously high levels of low-density lipoprotein cholesterol (LDL-C). This decision makes Evkeeza the first medication in the European Union approved...